Influenza continues to pose a significant global health burden, with seasonal outbreaks causing substantial morbidity and ...

The structure−activity relationship (SAR) of a novel hydrophobic binding interaction within a subsite of the influenza neuraminidase (NA) active site was characterized and optimized for a series of ...

BACKGROUND: Neuraminidase inhibitors (NIs) are stockpiled and recommended by public health agencies for treating and preventing seasonal and pandemic influenza.They are used clinically worldwide.

Influenza continues to pose a significant global health burden, with seasonal outbreaks causing substantial morbidity and mortality. Current ...

Cidara Therapeutics, a US biotech leveraging its Cloudbreak platform for next‑generation antivirals, saw its stock more than ...

The threat of an influenza pandemic has heightened the need for therapeutic strategies to combat this virus. This article provides a historical perspective on the discovery and development of two ...

The subtype [16 possible hemagglutinin and 9 possible neuraminidase subtypes]. ... The first influenza vaccine was a monovalent live-attenuated vaccine, which was used in Russia until recently.

Single doses of 450mg, 300mg and 150mg of CD388 conferred 76%, 61% and 58% protection, respectively, from symptomatic influenza over 24 weeks compared to placebo End of Phase 2 meeting request has ...

1 Introduction. Influenza viruses are the causative agent of pandemic influenza. In a typical influenza outbreak year, influenza can cause up to 5 million severe cases and 500,000 deaths ().To this ...

Neuraminidase inhibitors are a vital treatment option for patients with influenza." Roche concluded by claiming that other studies, including trials and real-world data have shown the drug's ...

Shares of San Diego-based Cidara Therapeutics Inc. (NASDAQ:CDTX) were trading at $40.41, up $19.39, or 92%, on positive top-line results from its randomized, double-blind, placebo-controlled phase IIb ...